| Outcome Measures: |
Primary: Number (Incidence) of adverse events (AEs), Measured as count of events., From baseline (week 0) to 26 weeks | Secondary: Number (Incidence) of hypoglycaemia Level 3 or Level 2, Hypoglycaemia Level 3 or Level 2 according to American Diabetes Association (ADA) guideline 2020 refers to: 1) Level 2: Glucose less than (\<) 54 milligrams per deciliter (mg/dL) (3.0 millimoles per liter \[mmol/L\]); 2) Level 3: A severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycaemia. Measured as count of events., From baseline (week 0) to 26 weeks|Change in glycated haemoglobin (HbA1c), Measured in percentage (%)., From baseline (week 0) to 26 weeks|Participants achieving HbA1c target <7.0%, Measured as count of participants (Yes/No)., At 26 weeks|Change in fasting blood glucose (FBG)/fasting plasma glucose (FPG), Measured in mg/dL., From baseline (week 0) to 26 weeks|Change in post prandial blood glucose (PPBG)/post prandial plasma glucose (PPPG), Measured in mg/dL., From baseline (week 0) to 26 weeks|Change in body weight, Measured in kilogram (kg)., From baseline (week 0) to 26 weeks|Dose of Rybelsus, Measured in milligrams per day (mg/day)., At 26 weeks
|
